Một số tài liệu về sán lá gan lớn Fasciola spp. kháng thuốc Triclabendazole trên thế giới
1.Devine C, Brennan GP, Lanusse CE, Alvarez LI, Trudgett A, Hoey E, et al. Potentiation of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica following its co-administration with the metabolic inhibitor, ketoconazole. Vet Parasitol. 2012;184:37–47. 2.Eberhard M, Engels D Fascioliasis. In: Heymann DL, editor. Control of communicable diseases manual, 19th ed. Washington (DC): American Public Health Association; 2008. p. 230–1. 3.Mas-Coma S, Valero MA, Bargues MD Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control. Adv Parasitol. 2009;69:41–146. 4.Wagener DJT, van Tongeren JHM, Meuwissen JHET Fasciola hepatica infection; an unusual cause of severe anemia [in Dutch] Ned Tijdschr Geneeskd. 1972;116:431–5. 5.Borgsteede FHM, Moll L, Vellema P, Gaasenbeek CPH Lack of reversion in triclabendazole-resistant Fasciola hepatica. Vet Rec. 2005;156:350–1. 6.Keiser J, Engels D, Buscher G, Utzinger J Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Investig Drugs. 2005;14:1513–26. 7.Fairweather I Reducing the future threat from (liver) fluke: realistic prospect or quixotic fantasy? Vet Parasitol. 2011;180:133–43. 8.Moll L, Gaasenbeek CPH, Vellema P, Borgsteede FHM Resistance of Fasciola hepatica against triclabendazole in cattle and sheep in the Netherlands. Vet Parasitol. 2000;91:153–8. 9.Gaasenbeek CPH, Moll L, Cornelissen JBWJ, Vellema P, Borgsteede FHM An experimental study on triclabendazole resistance of Fasciola hepatica in sheep. Vet Parasitol. 2001;95:37–43. 10.Tolan RW Jr. Fascioliasis due to Fasciola hepatica and Fasciola gigantica infection: an update on this 'neglected' neglected tropical disease. Lab Med. Feb 2011;42(2):107-117. 11.Fürst T, Duthaler U, Sripa B, Utzinger J, Keiser J. Trematode infections: liver and lung flukes. Infect Dis Clin North Am. Jun 2012;26(2):399-41. 12.Cabada MM, White AC Jr. New developments in epidemiology, diagnosis, and treatment of fascioliasis. Curr Opin Infect Dis. Oct 2012;25(5):518-22. 13.Alatoom A, Cavuoti D, Southern P, Gander R. Fasciola hepatica infection in the United States. Lab Med. July, 2008;39(7):425-8. 14.Haseeb AN, el-Shazly AM, Arafa MA, Morsy AT. A review on fascioliasis in Egypt. J Egypt Soc Parasitol. Apr 2002;32(1):317-54. 15.Fürst T, Keiser J, Utzinger J. Global burden of human food-borne trematodiasis: a systematic review and meta-analysis. Lancet Infect Dis. Mar 2012;12(3):210-21. 16.Youn H. Review of zoonotic parasites in medical and veterinary fields in the Republic of Korea. Korean J Parasitol. Oct 2009;47 Suppl:S133-41. 17.Lopez M, White AC Jr, Cabada MM. Burden of Fasciola hepatica Infection among Children from Paucartambo in Cusco, Peru. Am J Trop Med Hyg. Mar 2012;86(3):481-5. 18.Chand MA, Herman JS, Partridge DG, Hewitt K, Chiodini PL. Imported human fascioliasis, United kingdom. Emerg Infect Dis. Nov 2009;15(11):1876-7. 19.Dreyfuss G, Vignoles P, Rondelaud D. Fasciola hepatica: epidemiological surveillance of natural watercress beds in central France. Parasitol Res. Mar 2005;95(4):278-82. 20.el-Shabrawi M, el-Karaksy H, Okasha S, el-Hennawy A. Human fascioliasis: clinical features and diagnostic difficulties in Egyptian children. J Trop Pediatr. Jun 1997;43(3):162-6. 21.Nguyen TG, Le TH, De NV, et al. Assessment of a 27-kDa antigen in enzyme-linked immunosorbent assay for the diagnosis of fasciolosis in Vietnamese patients. Trop Med Int Health. Apr 2010;15(4):462-7. 22.Ai L, Dong SJ, Zhang WY, et al. Specific PCR-based assays for the identification of Fasciola species: their development, evaluation and potential usefulness in prevalence surveys. Ann Trop Med Parasitol. Jan 2010;104(1):65-72. 23.Le TH, Nguyen KT, Nguyen NT, Doan HT, Le XT, Hoang CT, et al. Development and evaluation of a single-step duplex PCR for simultaneous detection of Fasciola hepatica and Fasciola gigantica (family Fasciolidae, class Trematoda, phylum Platyhelminthes). J Clin Microbiol. Aug 2012;50(8):2720-6. 24.Keiser J, Duthaler U, Utzinger J. Update on the diagnosis and treatment of food-borne trematode infections. Curr Opin Infect Dis. Oct 2010;23(5):513-20. 25.Ubeira FM, Muiño L, Valero MA, Periago MV, Pérez-Crespo I, Mezo M. MM3-ELISA detection of Fasciola hepatica coproantigens in preserved human stool samples. Am J Trop Med Hyg. Jul 2009;81(1):156-62. 26.Chamadol N, Laopaiboon V, Techasatian P, Sukeepaisanjaroen W, Sripanuskul A. Computerized tomographic findings of hepatic fascioliasis compared with melioidosis-caused liver abscesses. J Med Assoc Thai. Jul 2010;93(7):838-48. 27.Cantisani V, Cantisani C, Mortele K, et al. Diagnostic imaging in the study of human hepatobiliary fascioliasis. Radiol Med. Feb 2010;115(1):83-92. 28.Bacq Y, Besnier JM, Duong TH, et al. Successful treatment of acute fascioliasis with bithionol. Hepatology. Dec 1991;14(6):1066-9. [Medline]. 29.el-Karaksy H, Hassanein B, Okasha S, Behairy B, Gadallah I. Human fascioliasis in Egyptian children: successful treatment with triclabendazole. J Trop Pediatr. Jun 1999;45(3):135-8. [Medline]. 30.Villegas F, Angles R, Barrientos R, Barrios G, Valero MA, Hamed K, et al. Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bolivian Altiplano. PLoS Negl Trop Dis. 2012;6(8):e1720. [Medline]. [Full Text]. 31.Winkelhagen AJ, Mank T, de Vries PJ, Soetekouw R. Apparent Triclabendazole-Resistant Human Fasciola hepatica Infection, the Netherlands. Emerg Infect Dis. Jun 2012;18(6):1028-9. [Medline]. 32.Dowidar N, El Sayad M, Osman M, Salem A. Endoscopic therapy of fascioliasis resistant to oral therapy. Gastrointest Endosc. Sep 1999;50(3):345-51. [Medline]. 33.Apt W, Aguilera X, Vega F, et al. Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response. Am J Trop Med Hyg. Jun 1995;52(6):532-5. [Medline]. 34.Falcón CR, Carranza FA, Aoki P, Motrán CC, Cervi L. Adoptive Transfer of Dendritic Cells Pulsed With Fasciola hepatica Antigens and Lipopolysaccharides Confers Protection Against Fasciolosis in Mice. J Infect Dis. Feb 2012;205(3):506-14. [Medline]. 35.Leon M, Alave J, Alvarado R, Gotuzzo E, Terashima A, Seas C. A 52-year-old woman with a subcapsular liver hematoma. Clin Infect Dis. May 2011;52(9):1137, 1195-6. [Medline]. 36.Arauco R, Zetola NM, Calderon F, Seas C. Human fascioliasis: a case of hyperinfection and an update for clinicians. Foodborne Pathog Dis. 2007;4(3):305-12. [Medline]. 37.Arjona R, Riancho JA, Aguado JM, Salesa R, Gonzalez-Macias J. Fascioliasis in developed countries: a review of classic and aberrant forms of the disease. Medicine (Baltimore). Jan 1995;74(1):13-23. [Medline]. 38.Ashrafi K, Valero MA, Massoud J, et al. Plant-borne human contamination by fascioliasis. Am J Trop Med Hyg. Aug 2006;75(2):295-302. [Medline]. 39.Bunnag D, Bunnag T, Goldsmith R. Liver fluke infections. In: Hunter's Tropical Medicine. 1991:818-27. 40.Cheng AC, Zakhidov BO, Babadjonova LJ, Rogers NK, McCollum CJ, Hillyer GV. A 6-year-old boy with facial swelling and monocular blindness. Clin Infect Dis. Nov 1 2007;45(9):1207, 1238-9. [Medline]. 41.Clark BM, Lloyd BA, Christopher GW, Foody WF. A young man from Peru with fever and abdominal pain. Clin Infect Dis. Mar 15 2005;40(6):842-3, 879-80. [Medline]. 42.Diaz E, Mondragon J, Ramirez E, Bernal R. Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. Am J Trop Med Hyg. Apr 2003;68(4):384-5. [Medline]. [Full Text]. 43.Dreyfuss G, Rondelaud D. Biodiversity of flukes. Parasite. Sep 2008;15(3):282-5. [Medline]. 44.Espinoza JR, Maco V, Marcos L, Saez S, Neyra V, Terashima A. Evaluation of Fas2-ELISA for the serological detection of Fasciola hepatica infection in humans. Am J Trop Med Hyg. May 2007;76(5):977-82. [Medline]. 45.Fox LM, Saravolatz LD. Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis. Apr 15 2005;40(8):1173-80. [Medline]. 46.Fried B, Abruzzi A. Food-borne trematode infections of humans in the United States of America. Parasitol Res. May 2010;106(6):1263-80. [Medline]. 47.Garcia HH, Moro PL, Schantz PM. Zoonotic helminth infections of humans: echinococcosis, cysticercosis and fascioliasis. Curr Opin Infect Dis. Oct 2007;20(5):489-94. [Medline]. 48.Graham CS, Brodie SB, Weller PF. Imported Fasciola hepatica Infection in the United States and Treatment with Triclabendazole. Clin Infect Dis. Jul 1 2001;33(1):1-5. [Medline]. 49.Gökçe M, Sahiner U, Unal S, Parlakay A, oncel I, Saçkesen C, et al. An unexpected parasitic cause of hypereosinophilia: fascioliasis. Turk J Pediatr. Jan-Feb 2011;53(1):111-3. [Medline]. 50.Hien TT, Truong NT, Minh NH, et al. A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in central Vietnam. Am J Trop Med Hyg. Mar 2008;78(3):388-92. [Medline]. 51.Kabaalioglu A, Apaydin A, Sindel T, Luleci E. US-guided gallbladder aspiration: a new diagnostic method for biliary fascioliasis. Eur Radiol. 1999;9(5):880-2. [Medline]. 52.Kaewpitoon N, Kaewpitoon SJ, Pengsaa P, Pilasri C. Knowledge, attitude and practice related to liver fluke infection in northeast Thailand. World J Gastroenterol. Mar 28 2007;13(12):1837-40. [Medline]. 53.Karabuli TA, Shaikhani MA, Karadaghi SH, Kasnazan KH. Education and imaging. Hepatobiliary and pancreatic: fascioliasis. J Gastroenterol Hepatol. Jul 2009;24(7):1309. [Medline]. 54.Katz M, Despommier DD, Gwadz RW. Fasciola hepatica. In: Parasitic Diseases. 1989:112-6. 55.Keiser J, Duthaler U, Utzinger J. Update on the diagnosis and treatment of food-borne trematode infections. Curr Opin Infect Dis. Oct 2010;23(5):513-20. [Medline]. 56.Keiser J, Utzinger J. Chemotherapy for major food-borne trematodes: a review. Expert Opin Pharmacother. Aug 2004;5(8):1711-26. [Medline]. 57.Keiser J, Utzinger J. Food-borne trematodiases. Clin Microbiol Rev. Jul 2009;22(3):466-83. [Medline]. [Full Text]. 58.Le TH, De NV, Agatsuma T, Blair D, Vercruysse J, Dorny P. Molecular confirmation that Fasciola gigantica can undertake aberrant migrations in human hosts. J Clin Microbiol. Feb 2007;45(2):648-50. [Medline]. 59.Lim JH, Kim SY, Park CM. Parasitic diseases of the biliary tract. AJR Am J Roentgenol. Jun 2007;188(6):1596-603. [Medline]. 60.Lim JH, Mairiang E, Ahn GH. Biliary parasitic diseases including clonorchiasis, opisthorchiasis and fascioliasis. Abdom Imaging. Mar-Apr 2008;33(2):157-65. [Medline]. 61.Liu LX, Harinasuta KT. Liver and intestinal flukes. Gastroenterol Clin North Am. Sep 1996;25(3):627-36. [Medline]. 62.Lopez-Velez R, Dominguez-Castellano A, Garron C. Successful treatment of human fascioliasis with triclabendazole. Eur J Clin Microbiol Infect Dis. Jul 1999;18(7):525-6. [Medline]. 63.L. Mottier, L. Alvarez, I. Fairweather, C. Lanusse (2006), Resistance-induced changes in triclabendazole transport in fasciola hepatica: ivermectin reversal effect , Journal of Parasitology 92(6):1355-1360. 2006 64.MacLean JD, Cross J, Mahanty S. Liver, lung, and intestinal fluke infections. In: Tropical Infectious Diseases: Principles, Pathogens, & Practice. 1999:1039-57. 65.Makay O, Gurcu B, Caliskan C, Nart D, Tuncyurek M, Korkut M. Ectopic fascioliasis mimicking a colon tumor. World J Gastroenterol. May 14 2007;13(18):2633-5. [Medline]. 66.Mannstadt M, Sing A, Leitritz L, Brenner-Maucher K, Bogner J. Conservative management of biliary obstruction due to Fasciola hepatica. Clin Infect Dis. Nov 2000;31(5):1301-3. [Medline]. 67.Mansour-Ghanaei F, Shafaghi A, Fallah MS. The effect of metronidazole in treating human fascioliasis. Med Sci Monit. Oct 2003;9(10):PI127-30. [Medline]. 68.Marcos L, Maco V, Samalvides F. Risk factors for Fasciola hepatica infection in children: a case-control study. Trans R Soc Trop Med Hyg. Feb 2006;100(2):158-66. [Medline]. 69.Devine C, Brennan GP, Lanusse CE, Alvarez LI, Trudgett A, Hoey E, Fairweather I (2011),Enhancement of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica by co-treatment with ketoconazole, Vet Parasitol. 2011 May 11;177(3-4):305-15. 70.Devine C, Brennan GP, Lanusse CE, Alvarez LI, Trudgett A, Hoey E, Fairweather I (2011), Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica, Parasitol Res. 2011 Oct;109(4):981-95. doi: 10.1007/s00436-011-2304-9. Epub 2011 Mar 26. 71.Marcos LA, Tagle M, Terashima A, et al. Natural history, clinicoradiologic correlates, and response to triclabendazole in acute massive fascioliasis. Am J Trop Med Hyg. Feb 2008;78(2):222-7. [Medline]. 72.Marcos LA, Terashima A, Gotuzzo E. Update on hepatobiliary flukes: fascioliasis, opisthorchiasis and clonorchiasis. Curr Opin Infect Dis. Oct 2008;21(5):523-30. [Medline]. 73.Mas-Coma S, Valero MA, Bargues MD. Chapter 2. Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control. Adv Parasitol. 2009;69:41-146. [Medline]. 74.McManus DP, Dalton JP. Vaccines against the zoonotic trematodes Schistosoma japonicum, Fasciola hepatica and Fasciola gigantica. Parasitology. 2006;133 Suppl:S43-61. [Medline]. 75.Nawa Y, Hatz C, Blum J. Sushi delights and parasites: the risk of fishborne and foodborne parasitic zoonoses in Asia. Clin Infect Dis. Nov 1 2005;41(9):1297-303. [Medline]. 76.Noyer CM, Coyle CM, Werner C, et al. Hypereosinophilia and liver mass in an immigrant. Am J Trop Med Hyg. Jun 2002;66(6):774-6. [Medline]. [Full Text]. 77.Pearson RD. Nitazoxanide As Treatment of Intestinal Parasites in Children. Curr Infect Dis Rep. Feb 2004;6(1):25-26. [Medline]. 78.Pearson RD, Weller PF, Guerrant. Chemotherapy of parasitic diseases. In: Tropical Infectious Diseases: Principles, Pathogens, & Practice. 1999:215-37. 79.Pilsczek FH. Helminthic infections mimicking malignancy: a review of published case reports. J Infect Dev Ctries. Aug 4 2010;4(7):425-9. [Medline]. 80.Price TA, Tuazon CU, Simon GL. Fascioliasis: case reports and review. Clin Infect Dis. Sep 1993;17(3):426-30. [Medline]. 81.Rana SS, Bhasin DK, Nanda M, Singh K. Parasitic infestations of the biliary tract. Curr Gastroenterol Rep. Apr 2007;9(2):156-64. [Medline]. 82.Richter J, Knipper M, Gobels K. Fascioliasis. Curr Treatment Options Infect Dis. 2002;4:313-7. 83.Robertson J, Shilkofski N. Drug doses. In: The Harriet Lane Handbook: A Manual for Pediatric House Officers. Philadelphia, Pa: Mosby; 2005:679-1009. 84.Sripa B, Kaewkes S, Intapan PM, Maleewong W, Brindley PJ. Food-borne trematodiases in Southeast Asia epidemiology, pathology, clinical manifestation and control. Adv Parasitol. 2010;72:305-50. [Medline]. 85.Sripa B, Kaewkes S, Sithithaworn P, Mairiang E, Laha T, Smout M. Liver fluke induces cholangiocarcinoma. PLoS Med. Jul 2007;4(7):e201. [Medline]. 86.Tantrawatpan C, Maleewong W, Wongkham C, et al. Serodiagnosis of human fascioliasis by a cystatin capture enzyme-linked immunosorbent assay with recombinant Fasciola gigantica cathepsin L antigen. Am J Trop Med Hyg. Jan 2005;72(1):82-6. [Medline]. [Full Text]. 87.Turner JA. Trematodes. In: Textbook of Pediatric Infectious Diseases. 2004:2817-25. 88.Valero MA, Santana M, Morales M, et al. Risk of gallstone disease in advanced chronic phase of fascioliasis: an experimental study in a rat model. J Infect Dis. Sep 1 2003;188(5):787-93. [Medline]. 89.Walker SM, McKinstry B, Boray JC, et al. Response of two isolates of Fasciola hepatica to treatment with triclabendazole in vivo and in vitro. Parasitol Res. Dec 2004;94(6):427-38. [Medline]. 90.Xuan le T, Hung NT, Waikagul J. Cutaneous fascioliasis: a case report in Vietnam. Am J Trop Med Hyg. May 2005;72(5):508-9. [Medline]. [Full Text]. 91.Yi-Zhu X, Zhi-Bang Y. A case of ectopic fascioliasis in the skin. Trop Doct. Oct 2010;40(4):253-4. [Medline]. 92.G.P. Brennan, I. Fairweather, A. Trudgett, E. Hoey et al (2008), Understanding triclabendazole resistance, Experimental and Molecular Pathology, Volume 82, Issue 2, p 104–109 93.Sargison, Neil et al., (2012), Diagnosis of triclabendazole resistance in Fasciola hepatica, Journal of the British Veterinary Association;8/11/2012, Vol. 171 Issue 6, p151. 94.Mas-Coma S, Bargues MD, Valero MA (2005). "Fascioliasis and other plant-borne trematode zoonoses". Int. J. Parasitol. 35 (11-12): 1255–78. 95.Torgerson, P; Claxton J (1999). "Epidemiology and control.". in Dalton, JP. Fasciolosis. Wallingford, Oxon, UK: CABI Pub. pp. 113–49. ISBN 0-85199-260-9. 96.Spithill, TW; Smooker PM, Copeman DB (1999). "Fasciola gigantica: epidemiology, control, immunology and molecular biology". in Dalton, JP. Fasciolosis. Wallingford, Oxon, UK: CABI Pub. pp. 465–525. ISBN 0-85199-260-9. 97.Anonymus (1995). Control of Foodborne Trematode Infections. WHO Technical Series No. 849. WHO, Geneva, 157 pp. 98.Singh, K.P., Srivastava, V.K., Prasad, A. and Pandey, A.P., 1994. Pathology due to Fasciola jacksoni in Indian elephants Elephas indicus. Ind. J. Anim. Scien. 64, 802–804. 99.Chen, M.G., Mott, K.E (1990). Progress in assessment of morbidity due to Fasciola hepatica infection: a review of recent literature. Trop. Dis. Bull. 87, R1–R38. 100.Mas-Coma, S; Bargues MD, Esteban JG (1999). "Human fasciolosis.". in Dalton, JP. Fasciolosis. Wallingford, Oxon, UK: CABI Pub. pp. 411–34. ISBN 0-85199-260-9. 101.Esteban, J.G., Bargues, M.D., Mas-Coma, S (1998). Geographical distribution, diagnosis and treatment of human fascioliasis: a review. Res. Rev. Parasitol. 58, 13–42. 102.Yilmaz H, Gödekmerdan A (2004). "Human fasciolosis in Van province, Turkey". Acta Trop. 92 (2): 161–2. 103.Mas-Coma, S., Rodriguez, A., Bargues, M.D., Valero, M.A., Coello, J., Angles, R.(1998). Secondary reservoir role of domestic animals other than sheep and cattle in fascioliasis transmission on the northern Bolivian Altiplano. Res. Rev. Parasitol. 57, 39–46. 104.Mas-Coma, S., Fons, R., Feliu, C., Bargues, M.D., Valero, M.A., Galán-Puchades, M.T., 1988. Small mammals as natural definitive hosts of the liver fluke, Fasciola hepatica Linnaeus, 1758 (Trematoda: Fasciolidae): a review and two new records of epidemiologic interest on the island of Corsica. Rivista di Parassitologia 5, 73–78. 105.Menard, A., Agoulon, A., L’Hostis, M., Rondelaud, D., Collard, S., Chauvin, A., 2001. Myocastor coypus as a reservoir host of Fasciola hepatica in France. Vet. Res. 32, 499–508. 106.Markell, E.K., Voge, M., 1999. Medical Parasitology, eighth ed.. Saunders Company Publication, pp. 185–188. 107.Bjorland, J., Bryan, R.T., Strauss, W., Hillyer, G.V., McAuley, J.B., 1995. An outbreak of acute fascioliasis among Aymara Indians in the Bolivian Altiplano. Clin. Infect. Dis. 21, 1228–1233. 108.Taira, N., Yoshifuji, H., Boray, J.C., 1997. Zoonotic potential of infection with Fasciola spp. by consumption of freshly prepared raw liver containing immature flukes. Int. J. Parasitol. 27, 775–779. 109.Graczyk, TK; Fried B (1999). "Development of Fasciola hepatica in the intermediate host.". in Dalton, JP. Fasciolosis. Wallingford, Oxon, UK: CABI Pub. pp. 31–46. ISBN 0-85199-260-9. 110.Behm, C.A., Sangster, N.C., 1999. Pathology, pathophysiology and clinical aspects. In: Dalton, J.P. (Ed.), Fasciolosis. CAB International Publishing, Wallingford, pp. 185–224. 111.Boray JC (1969). "Experimental fascioliasis in Australia". Adv. Parasitol. 7: 95–210. 112.Facey, R.V., Marsden, P.D., (1960). Fascioliasis in man: an outbreak in Hampshire. Brit. Med. J. ii, 619–625. 113.Anderson, P.H., Matthews, J.G., Berrett, S., Brush, P.J., Patterson, D.S.,(1981). Changes in plasma enzyme activities and other blood components in response to acute and chronic liver damage in cattle. Res Vet Sci. 31, 1-4. 114.Sykes, A.R., Coop, A.R., Robinson, M.G., (1980). Chronic subclinical ovine fascioliasis: plasma glutamate dehydrogenase, gamma glutamyl transpeptidase and aspartate aminotransferase activities and their significance as diagnostic aids. Res. Vet. Sci. 28, 71–78. 115.Haroun ET, Hillyer GV (1986). "Resistance to fascioliasis--a review". Vet. Parasitol. 20 (1-3): 63–93. 116.Phiri IK, Phiri AM, Harrison LJ (2006). "Serum antibody isotype responses of Fasciola-infected sheep and cattle to excretory and secretory products of Fasciola species". Vet. Parasitol. 141 (3-4): 234–42. 117.Merck Veterinary Manual - Infectious Necrotic Hepatitis. 118.Van Milligen FJ, Cornelissen JB, Bokhout BA (1998). "Location of induction and expression of protective immunity against Fasciola hepatica at the gut level: a study using an ex vivo infection model with ligated gut segments". J. Parasitol. 84 (4): 771–7. 119.Chauvin A, Bouvet G, Boulard C (1995). "Humoral and cellular immune responses to Fasciola hepatica experimental primary and secondary infection in sheep". Int. J. Parasitol. 25 (10): 1227–41. 120.Martínez-Moreno A, Martínez-Moreno FJ, Acosta I, Gutiérrez PN, Becerra C, Hernández S (1997). "Humoral and cellular immune responses to experimental Fasciola hepatica infections in goats". Parasitol. Res. 83 (7): 680–6. 121.Roberts JA, Estuningsih E, Wiedosari E, Spithill TW (1997). "Acquisition of resistance against Fasciola gigantica by Indonesian thin tail sheep". Vet. Parasitol. 73 (3-4): 215–24. 122.Wamae, L.W., (1996). Comparative pathogenesis and immunochemistry analysis of Fasciola gigantica infection in cattle and sheep. PhD Thesis. University of Edinburgh. 123.Hillyer, GV (1988). "Fascioliasis and fasciolopsiasis.". in A. Turano; Balows, Albert; M. Ohashi. Laboratory diagnosis of infectious diseases: principles and practices. 1: Bacterial, mycotic, and parasitic diseases. Berlin: Springer-Verlag. pp. 856–62. ISBN 0-387-96755-9. 124.Hillyer, GV (1999). "Immunodiagnosis of human and animal fasciolosis.". in Dalton JP. Fasciolosis. Wallingford, Oxon, UK: CABI Pub. pp. 435–47. ISBN 0-85199-260-9. 125.O'Neill SM, Parkinson M, Strauss W, Angles R, Dalton JP (1998). "Immunodiagnosis of Fasciola hepatica infection (fascioliasis) in a human population in the Bolivian Altiplano using purified cathepsin L cysteine proteinase". Am. J. Trop. Med. Hyg. 58 (4): 417–23. 126.Zimmerman GL, Jen LW, Cerro JE, Farnsworth KL, Wescott RB (December 1982). "Diagnosis of Fasciola hepatica infections in sheep by an enzyme-linked immunosorbent assay". Am. J. Vet. Res. 43 (12): 2097–100. 127.Duménigo BE, Espino AM, Finlay CM, Mezo M (2000). "Kinetics of antibody-based antigen detection in serum and faeces of sheep experimentally infected with Fasciola hepatica". Vet. Parasitol. 89 (1-2): 153–61. 128.Savioli L, Chitsulo L, Montresor A (1999). "New opportunities for the control of fascioliasis". Bull. World Health Organ. 77 (4): 300. 129.Rossignol JF, Abaza H, Friedman H (1998). "Successful treatment of human fascioliasis with nitazoxanide". Trans. R. Soc. Trop. Med. Hyg. 92 (1): 103–4. 130.Ramachandran, A., 2000. Pharmacology Recall. 131.Fairweather I, Boray JC (September 1999). "Fasciolicides: efficacy, actions, resistance and its management". Vet. J. 158 (2): 81–112. 132.Overend DJ, Bowen FL (July 1995). "Resistance of Fasciola hepatica to triclabendazole". Aust. Vet. J. 72 (7): 275–6. 133.O’Brien, D.J., 1998. Fasciolosis: a threat to livestock. Irish Vet. J. 51, 539–541. 134.Mitchell GB, Maris L, Bonniwell MA (1998). "Triclabendazole-resistant liver fluke in Scottish sheep". Vet. Rec. 143 (14): 399. 135.Moll L, Gaasenbeek CP, Vellema P, Borgsteede FH (2000). "Resistance of Fasciola hepatica against triclabendazole in cattle and sheep in The netherlands". Vet. Parasitol. 91 (1-2): 153–8. 136.Ibarra F, Vera Y, Quiroz H, et al (2004). "Determination of the effective dose of an experimental fasciolicide in naturally and experimentally infected cattle". Vet. Parasitol. 120 (1-2): 65–74.
|
TRANG CHỦ
